The Costs and Cost-Effectiveness of a District-Strengthening Strategy to Mitigate the 3 Delays to Quality Maternal Health Care: Results From Uganda and Zambia

Abstract

A comprehensive district-strengthening approach to address maternal and newborn health was estimated to cost US$177 per life-year gained in Uganda and $206 per life-year gained in Zambia. The approach represents a very cost-effective health investment compared to GDP per capita.

Health equity and COVID-19: global perspectives

“…With limited resources, most countries in SSA will divert funds to the fight against covid-19 and neglect other conditions such as malaria, maternal and child health conditions, and tuberculosis which account for some of the highest death rates among the poor and account for a substantial share of the disease burden. For example, In Zambia, like many African countries, maternal and newborn conditions, cause substantial mortality, are costly [38], and access to health facilities is important. Previous studies have shown that during pandemics, all-cause mortality rises substantially [39].…”

Saving Lives Together: A Qualitative Evaluation of the Saving Mothers, Giving Life Public-Private Partnership

“…It also meant that Uganda and Zambia would likely remain the focus of SMGL through the second phase of the initiative as OGAC was a major funder. (For more information on costs, incremental costs, and incremental cost per death averted in these 2 SMGL countries, see the companion article by Johns et al 8 in this supplement. )…”

Sustainability and Scale of the Saving Mothers, Giving Life Approach in Uganda and Zambia

“…A separate study in this supplement by Ben Johns et al 29 was conducted to determine costs—incremental costs and incremental cost per death averted—of the SMGL district strengthening approach. They found that the incremental cost for maternal and newborn care per SMGL-supported district in 2016 was US$845,000 in Uganda and US$760,000 in Zambia.…”

“…The district strengthening approach, as demonstrated in SMGL, represents a substantial cost-effective health investment, one that low- and middle-income countries can afford 29 …”